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Cervical cancer is almost invariably associated with infection by human papilloma-
virus. It is believed that the host genetic factors such as inflammation-induced cyto-
kines may play a role in cervical carcinogenesis. The IL1B gene, encoding IL-1
cytokine, contains several single nucleotide polymorphisms. One of them which is
in the positions -511 (C-T) related with promoter region has been associated with
increased IL-1 production and with increased risk of developing a number of inflam-
matory diseases and gastric carcinoma. We assessed the association between
the IL1B -511 polymorphism and cervical cancer risk in a hospital-based case-con-
trol study among 546 Korean women (182 cases; 364 age-matched controls). The
allele frequencies of the case subjects (C, 0.42; T, 0.58) were not significantly differ-
ent from those of control subjects (C, 0.43; T, 0.57). Control subjects were in Hardy-
Weinberg equilibrium. The carriers with -511 C/T or T/T genotypes were at higher
risk of cervical cancer with odds ratio of 2.42 (95% CI 1.31-4.46, p<0.005). How-
ever, there was no difference of cervical cancer risk between C/T heterologous
genotypes and T/T homologous genotypes. In conclusion, in Korean population,
IL1B -511 C/C genotypes were significantly associated with a decreased risk of
cervical cancer.
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INTRODUCTION
Cervical cancer is the second major cause of cancer-related
mortality in women worldwide and accounts for 250,000
deaths each year (1). It is well established that the infection
with high-risk types of human papillomavirus (HPV) plays
a central role in the pathogenesis of invasive cervical cancer
(2). Although many women are infected with high-risk types
of HPV, only a subset of infected women develops cervical
cancer, suggesting that other cofactors including host genetic
factors must be present for the development of malignancy.
Chronic inflammation has been shown to be an important
risk factor for a variety of epithelial cancers (3). Cytokines, as
the products of host response to inflammation, play an impor-
tant role in the defense against viral infections. In cervical
cancers, a number of previous reports suggested that chron-
ic inflammation is associated with the precancerous intra-
epithelial lesion and cancer of uterine cervix (4-6).
The interleukin-1 family of cytokines consists of several
members including ineterleukin-1 alpha, interleukin-1 beta
and interleukin-1 receptor antagonist. The genes for these
cytokines are clustered within a 430-kb segment on human
chromosome 2. These cytokines are produced by several cell
types and have multiple biological effects. Interleukin-1 beta
is a pro-inflammatory cytokine mainly produced by blood
monocytes and tissue macrophages and has been implicated
in mediating both acute and chronic inflammation (7). Recen-
tly, a common polymorphic allele of the regulatory region
of the IL1B gene was found to be associated with increased
IL-1 production (8). Also, the polymorphism in IL1B was
associated with various human cancers (8-11). Since there
were several reports supporting the positive association with
increased IL1B secretion and cervical cancer risk (12, 13), we
hypothesized that an individual with a IL1B genotype pro-
ducing more IL1B might have an increased risk of cervical
cancer. The C>T polymorphism in IL1B -511 site has been
correlated with increased intracellular IL1B levels in the pre-
vious reports (14). Here we report results from a hospital based
case-control study examining the association of IL1B -511
C>T polymorphisms with the risk of cervical cancer.
MATERIALS AND METHODS
Subjects 
Case subjects were selected from among cervical cancer
patients treated between April 1996 and July 2002 at the
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Seoul National University Hospital. A total of 182 patients
with confirmed cervical squamous cell carcinoma consented
to participate in the study and provided a blood specimen.
Age-matched (1:2) control subjects were comprised of 364
healthy, unrelated, cancer-free subjects recruited from visitors
who attended a comprehensive screening clinic at the same
institution and agreed to participate in this study. Informed
consent was received from all the cases and controls. All case
and control subjects were Korean, and the Institutional Re-
view Board of Seoul National University Hospital approved
the protocol used in this study.
Genotyping
All genotyping of 182 cases and 364 control samples was
performed by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP). In brief, IL1B -511 C>T
polymorphism was distinguished by PCR-RFLP, using the
known primer pairs (forward primers 5′ -GCCTGAACCCT-
GCATACCGT; reverse primers 5′ GCCAATAGCCCTCCC-
TGTCT-3′ ) and restriction enzyme AvaI. Amplification was
performed in a volume of 25  L, containing 2.5  L of 10×
PCR buffer (100 mM Tris-HCI, 15 mM MgCl2, and 500
mM KCl, pH 8.3), 200 nM each dNTP (Roche Diagnostics
Korea, Seoul, Korea), 1  M each primer (Bioneer, Daejeon,
Korea), 1 U Taq DNA polymerase (Roche Diagnostics Korea,
or Takara Shuzo, Otsu, Japan), and 100 ng of genomic DNA.
The thermocycling conditions were as follows: 95℃ for 5
min; then 35 cycles of 95℃ for 30 sec, 58-60℃ for 30 sec,
and 72℃ for 1 min; then 72℃ for 10 min. Fifteen micro-
liters of the reaction mixture was treated with 5 U of AvaI
(NE Biolabs, Beverly, MA, U.S.A.) at 37℃ for 12 hr and
subsequently analyzed on 3% agarose (2% Nusieve [Bio-
Whittaker Molecular Applications, Rockland, ME, U.S.A.]
and 1% agarose) gel.
Statistical analysis
Hardy-Weinberg equilibrium analyses were performed to
compare observed and expected genotype frequencies using
the chi-square test (D.F.=1). Allele frequency differences bet-
ween cases and controls were analyzed using the Pearson chi-
square test. Cervical cancer risk was estimated by odds ratios
(ORs) and 95% confidence intervals (CIs) using conditional
logistic regression model after adjustment for age.
RESULTS
In Korean population, we observed that the allelic frequen-
cies of the 182 case subjects (C, 0.42; T, 0.58) were not sig-
nificantly different from those of the 364 control subjects
(C, 0.43; T, 0.57). The allelic frequencies of control subjects
were not statistically different from those reported for Kore-
an populations by other investigators (9). The alleles were
in Hardy-Weinberg equilibrium only in control subjects.
We found that carriers of the T allele had a significantly
increased risk of cervical cancer. The frequency distribution
of the different genotypes for the IL1B -511 C>T polymor-
phism is shown in Table 1. The CC genotype was less frequ-
ent among the case subjects than among the control subjects
(7.7% and 16.8%, respectively). With the use of the chi-sq-
uare test, we found the significant difference in genotype fre-
quencies between case and control subjects (p<0.001).
Using the CC genotype as the reference genotype, we per-
formed logistic regression analysis with adjustment for age
variable. The CT genotype was associated with significantly
elevated OR of 2.83 (95% CI=1.52 to 5.28, p<0.001). Also,
the TT genotype was associated with elevated OR of 1.68
(95% CI=0.85 to 3.32, p=0.136). When we combined CT
and TT genotypes together, we found that CT and TT geno-
types were associated with OR of 2.42 (95% CI=1.31 to
4.46, p<0.005).
DISCUSSION
Here we reported that -511 polymorphism in IL1B gene
was associated with the risk of cervical cancer. Our findings
in this hospital-based case-control study suggest that the car-
riers of -511 T allele may be at increased risk of developing
cervical cancer. Our results support the previous hypothesis
that -511 T allele is associated with increased production of
IL-1 , and that IL-1 may play a role as host factors promot-
ing cervical carcinogenesis.
Since it is assumed that the host immune system is impor-
tant in the surveillance of HPV-related cervical neoplasia,
cytokines, including IL-1 , have been frequently correlated
to a risk of cervical cancer. The level of the IL-1 was increased
in the cervicovaginal washings of patients with cervical can-
cer (13). Individuals with high and intermediate IL-1 sec-
retor phenotypes may be more susceptible to lower grade
lesions rather than high grade lesion or cervical carcinoma
(12). Elevated vaginal lavage IL-1 was associated with a
high odds ratio of cervical dysplasia (15). These evidences,
OR, odds ratio; CI, confidence interval. OR was calculated by logistic
regression analysis adjusted for the age.
Controls (%) Cases (%) OR (95% CI) p
General genotype
CC 61 (16.8) 14 (7.7) 1.00 (ref.)
CT 194 (53.3) 126 (69.2) 2.83 (1.52-5.28) <0.001
TT 109 (29.9) 42 (23.1) 1.68 (0.85-3.32) 0.136
Dominant genotype
CC 61 (16.8) 14 (7.7) 1.00 (ref.)
CT+TT 303 (83.2) 168 (92.3) 2.42 (1.31-4.46) <0.005
Table 1. IL1B -511 polymorphism and the risk of cervical can-
cer in Korean women112 S. Kang, J.W. Kim, N.H. Park, et al.
including the results of this study, suggest that IL-1 may
be involved in early step of cervical carcinogenesis and that
individual difference of IL-1 secretion may affect individ-
ual susceptibility to cervical cancer progression.
The polymorphism of IL1B gene was reported to be asso-
ciated with various diseases including cancer, but it is most
intensively studied in gastric cancer. El-Omar et al. have re-
cently reported that proinflammatory genotypes of the inter-
leukin-1 gene cluster (IL1B -511/-31 and IL-1RN*2/*2)
were associated with increased risk of gastric cancer and its
presumptive precursors, gastric atrophy and hypochlorhydria,
in white populations from Poland and Scotland (8). Their
results contained data that IL1B -511 C>T polymorphism
was associated with risk of gastric cancer. While explaining
this, they addressed that there were no differences in bind-
ing activity between IL1B -511 genotypes, indicating that
the effect of IL1B -511 polymorphism may be mediated by
linkage disequilibrium with the TATA box polymorphism.
This may be possible explanation of our finding, no gene-
dosage relationship between -511 genotypes. In consistence
with our data, another recent study reported that IL1B -511
CT heterozygous genotype was the main risk of intestinal
type gastric cancer in Korean population (9).
Since our results is the first report about the association
between IL1B -511 C>T polymorphism and the risk of cer-
vical cancer, we could not compare our results with other
data. However, there were several previous reports suggest-
ing the possible association between cervical cancer risk and
the polymorphism of other cytokines or cytokine receptors,
such as TNF-alpha, interleukin 10, and interleukin 1 recep-
tor antagonist (16-21). Therefore, it can be speculated that
functional variation of inflammatory cytokine may influence
on the individual susceptibility of cervical cancer.
Degradation of the p53 gene by oncogenic HPV E6 protein
is the most well known carcinogenic mechanism in human
cervical cancer. Recent findings indicate an increased p53
mutation load or altered p53 protein function in a number
of inflammatory diseases (22). It has been shown that, in rats,
intratracheal instillation of IL-1 caused hydrogen peroxide
production in lung tissue, initiated neutrophil influx and
stimulated their release of reactive oxygen species (23). There-
fore, it can be speculated that reactive free radicals produced
by inflammatory cells may cause DNA damage in epithelial
cells. Inflammatory cytokines have also been shown to induce
DNA damage and inhibit DNA repair in vitro (24). In addi-
tion, IL-1 has been shown to reduce apoptosis by changing
the ratio of BCL-2/BAX proteins (25). Therefore, a higher
production of IL-1 may lead to increased p53 mutation load,
and the increased level of IL-1 may play a role not only in
HPV-related cervical carcinogenesis but also in HPV-non-
related cervical carcinogenesis.
The limitations of the present study are as follows. First,
the present study is hospital-based and retrospective in nature.
Therefore, it cannot be free from any selection bias. Second,
our sample size is so limited that it has not enough statisti-
cal power to exclude the existence of gene-dosage relation-
ship. Third, the various epidemiologic risk factors of cervical
cancer, such as smoking, alcohol intake, diet, or sexual beha-
vior, were not included for analysis. Fourth, since our study
did not include all clustered polymorphic site of IL1B and
associated genes, the haplotype analysis could not be done.
So, it would be worthwhile to perform further large-scale
population-based study including the analysis of various clus-
tered polymorphisms. It also should be noted that the risk
of cancer caused by foreign pathogen such as virus or bacte-
ria was repeatedly reported by numerous study (8, 26). There-
fore, it can be speculated that increased IL-1 production
may be associated with host genetic factor defending from
foreign carcinogenic pathogen.
In conclusion, in Korean population, IL1B -511 CC geno-
type was significantly associated with decreased risk of cer-
vical cancer. This relationship supports the idea that polymor-
phism of inflammatory response genes may be host genetic
susceptibility to cervical cancer. IL1B polymorphism should
be considered as candidate genetic factor in future study elu-
cidating the genetic risk of cervical cancer.
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